Retinal Vein Occlusion Market 2021 Growth Drivers, Business Strategies and Future Prospects 2026 | Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Ellex Medical Lasers, GlaxoSmithKline Plc., IRIDEX Corporation, Novartis, Quantel Medical

Retinal Vein Occlusion Market Report provides detailed analysis of Growth Factors of the market as well as it gives an analysis of the Market size, Latest trends, SWOT Analysis by Regions and Forecasted market research data until 2025. The Retinal Vein Occlusion market report has studied key opportunities in the market and influencing factors which are useful to the business. The report also maps the qualitative and quantitative impact of various market factors like macro-economic indicators, PPP, Epidemiological data, Insurance scenario and patent and IP information, Government Policies and business regulations along market attractiveness as per segments.

Retinal Vein Occlusion Market is valued at USD 1.27 Billion in 2017 and expected to reach USD 2.93 Billion by 2026 with a CAGR of 8.5% (approx.) over the forecast period.

Get Sample Copy Of This Report + All Related Graphs (Covid-19 Update):

https://www.marketinsightsreports.com/reports/07222157994/global-retinal-vein-occlusion-market-size-status-and-forecast-2020-2026/inquiry?source=OpenPr&Mode=12                   

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Retinal Vein Occlusion Market: Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Ellex Medical Lasers, GlaxoSmithKline Plc., IRIDEX Corporation, Novartis, Quantel Medical Inc., Topcon Medical Systems, Inc., ZEISS, Lumenis, Sanofi Aventis, Bausch Health, Alimera Sciences, Fovea Pharmaceuticals SA, Icon Biosciences, Suzuken Co.Ltd., Genentech, Inc., Ranbaxy Pharmaceuticals and others.

Retinal vein occlusion, one of the most frequently occurring retinal vascular disorders in elderly patients, develops predominantly in individuals over age 65 years. The main risk factors for RVO include age and systemic vascular disorders. It is categorized into central RVO (CRVO) and branch RVO (BRVO) according to the site of blockage in the retinal vein. CRVO is divided further into nonischemic and ischemic types according to the perfusion status based on fluorescein angiography. BRVO consists of major branch RVO (when one of the major branch retinal veins is occluded, usually near, or rarely at, the optic disc) and macular branch RVO (when only one of the macular venules is occluded).Macular edema is the major complication of significant visual loss in patients with CRVO and BRVO, and various treatments have been used to improve macular edema and cause regression of intraocular neovascularization.

Industry News and Developments:

Bayer Receives Approval for EYLEA® in Japan for the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion

Berlin, November 22, 2013 – Bayer HealthCare has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for EYLEA® (aflibercept solution for injection) for the treatment of macular edema secondary to central retinal vein occlusion (CRVO).

“The additional approval of EYLEA in Japan for the treatment of macular edema secondary to CRVO is great news for patients in Japan suffering from this potentially sight-threatening eye condition,” said Kemal Malik, M.D., Member of the Bayer HealthCare Executive Committee and Head of Global Development. “The loss of vision not only impacts patients but also their families’ lives.”

VEGF Trap-Eye has been approved under the brand name EYLEA® in Europe, the United States, Japan, Australia, and in many other countries for the treatment of patients with neovascular age-related macular degeneration (wet AMD). EYLEA has also been approved in Europe for the treatment of visual impairment due to macular edema secondary to CRVO as well as in the U.S. and in selected countries in Asia and Latin America for the treatment of macular edema following CRVO.

EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Retinal Vein Occlusion

TARRYTOWN, N.Y., Feb. 26, 2015 -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Retinal Vein Occlusion (RVO). The new indication includes Macular Edema following Branch Retinal Vein Occlusion (BRVO) in addition to the previously approved indication of Macular Edema secondary to Central Retinal Vein Occlusion (CRVO). The recommended treatment approach in the European Union (EU) is to initiate the therapy with one injection per month, continuing monthly treatment until maximum visual acuity is achieved and/or there are no signs of disease activity. Treatment may then be continued with a treat and extend regimen with gradually increased treatment intervals to maintain stable visual and/or anatomic outcomes.

EU approval is based on positive data from the Phase 3 VIBRANT study in patients with visual impairment due to macular edema secondary to BRVO.

EYLEA is approved in the United States for the treatment of neovascular (wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), which includes both CRVO and BRVO, and Diabetic Macular Edema (DME). EYLEA is also approved in the EU and other markets for use in wet AMD and DME.

Global Retinal Vein Occlusion Market Split by Product Type and Applications:

This report segments the market on the basis of Types are:

Branch Retinal Artery Occlusion
Central Retinal Vein Occlusion

On the basis of Application, the market is segmented into:

Hospitals and Clinics
Research and Academics
Others

Buy The Report:
https://www.marketinsightsreports.com/report/purchase/07222157994?mode=su?source=OpenPr&Mode=12                         

Regional Analysis For Retinal Vein Occlusion Market:

For comprehensive understanding of market dynamics, the global Retinal Vein Occlusion market is analyzed across key geographies namely:

North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Retinal Vein Occlusion Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger and acquisitions along with trending innovation and business policies are reviewed in the report. The report contains basic, secondary and advanced information pertaining to the Market global status and trend, market size, share, growth, trends analysis, segment and forecasts from 2021–2025.                 

Key Points of Retinal Vein Occlusion Market Table of Contents:

-Market Overview: The report begins with this section where a product overview and key content on the product and application segments of the global Halal Foods market are provided. The highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

-Competition by company: Here we analyze the competition of the global Retinal Vein Occlusion market, by company price, revenue, sales and market share, market share, competitive landscape, and latest trends, mergers, expansions, acquisitions, and market share of top companies.

-Company Profile and Sales Data: As the name suggests, this section provides sales data and useful information about the business of key players in the global Retinal Vein Occlusion market. It describes the key businesses of gross margin, price, revenue, products and specifications, types, applications, competitors, manufacturing base, and key players operating in the global Retinal Vein Occlusion market.

-Market Forecast: Here the report provides a full forecast for the global Retinal Vein Occlusion market by product, application, and region. It also provides global sales and revenue forecasts for all years in the forecast period.

-Research Results and Conclusion: One of the last sections of the report where analyst findings and findings are provided.

For More Information On This Report, Please Visit: https://www.marketinsightsreports.com/reports/07222157994/global-retinal-vein-occlusion-market-size-status-and-forecast-2020-2026?source=OpenPr&Mode=12                

Due to the onset of COVID-19 pandemic, several economies across the world have experienced harsh economic downturn. The industrialists across North America, Europe, Asia Pacific, Latin America and Middle East and Africa were facing problems due to changing preferences of the customers and demand fluctuation. The market research report covers pre-Covid-19 data for the Retinal Vein Occlusion market in years 2018 and 2020. Further, the report also covers forecast Covid-19 data from 2021 to 2027, which provides future outlook of the market for the manufacturers and suppliers.

Browse Related Reports:

Occlusion Catheters Market:  

https://www.marketinsightsreports.com/reports/05272939254/global-occlusion-catheters-market-2021-by-manufacturers-regions-type-and-application-forecast-to-2026?source=OpenPr&Mode=12                      

Retinal Vein Occlusion Drug Market:

https://www.marketinsightsreports.com/reports/06022957245/2016-2028-global-retinal-vein-occlusion-drug-industry-market-research-report-segment-by-player-type-application-marketing-channel-and-region?source=OpenPr&Mode=12                          

Occlusion Microcatheter Market:

https://www.marketinsightsreports.com/reports/05042864633/global-occlusion-microcatheter-sales-market-report-2021?source=OpenPr&Mode=12                  

Customization Of The Report:

MarketInsightsReports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.     

If you have any questions about any of our “Retinal Vein Occlusion market report” or would like to schedule a personalized free demo of Retinal Vein Occlusion market report, please do not hesitate to contact me at irfan@marketinsightsreports.com.

Best wishes,

Irfan Tamboli

Head of Sales Operations

Market Insights Reports

Tel: + 1704 266 3234 | +91-750-707-8687

Email: sales@marketinsightsreports.com | irfan@marketinsightsreports.com

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides Global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

This release was published on openPR.